Medical Supply and Equipment Business Investment Opportunities

Established disposable medical consumables manufacturer specializing in surgical gowns, surgical drapes, and customized drape pack kits for hospitals and healthcare facilities. - Focuses exclusively on single-use disposable products designed to support infection control, hygiene, and patient safety in clinical environments. - Supplies products directly to hospitals, healthcare institutions, and medical facilities through a B2B sales model. - Maintains an active customer base of 15–20 hospitals and healthcare organizations, generating recurring demand for essential medical consumables. - Current production capacity includes approximately 700 surgical gowns per day, operating at around 50% utilization. - Surgical drape manufacturing capacity is approximately 500 units per day, with the ability to increase output to around 800 units daily. - Revenue is generated through the manufacture and sale of disposable surgical products used in operating rooms, clinics, and healthcare settings. - Operates in a growing healthcare segment driven by increasing awareness of infection prevention and the widespread adoption of disposable medical products. - Established approximately six years ago and has built operational expertise in medical consumables manufacturing and hospital supply requirements. - Holds a valid Drug License, supporting regulatory compliance and product credibility within the healthcare sector. - Well-positioned to expand production, increase capacity utilization, and broaden its customer base as demand for disposable healthcare products continues to grow.

• Global consumer healthcare company focused on smoking harm reduction through patented, drug-free nicotine and tar reduction technology. • Core product is a liquid solution applied to cigarette filters that blocks up to 99% of tar and nicotine while allowing adult smokers to maintain their normal smoking ritual. • Targets adult smokers seeking harm reduction and gradual smoking cessation without prescription drugs or behavioural disruption. • Operates a scalable contract-manufacturing and distribution-led model with sales channels across OTC retail, pharmacies, government health programmes, and international distribution partnerships. • Built around proprietary technology with worldwide patents and trademarks protected until 20 years from now, creating long-term defensibility in the smoking cessation sector. • Regulatory clearances and ingredient approvals secured across major markets, including FDA-approved ingredients in the USA, NHS ethical clearance in the UK, TGA Australia, and approvals across 40+ countries. • Established international footprint with active or contracted distribution and government programmes across GCC countries, Africa, Australia, New Zealand, China, Japan, Singapore, Malaysia, Indonesia, Greece, and Cyprus. • Additional platform extensions planned for cigarette filter capsules, government smoking-reduction tenders, and solutions designed for the global hookah and shisha market. • Positioned to address the growing global smoking cessation and harm-reduction market estimated at over $25 billion, serving approximately 1.1 billion smokers worldwide. • Reports strong financial performance with EBITDA margins of approximately 40%, fully audited financial statements, and no bank borrowings. • Asset-light operating structure enables rapid scalability while maintaining strong profitability and international expansion flexibility. • Management has developed a long-term intellectual property monetisation strategy with an indicative IP valuation target of approximately $50 million in the next 6 years. • Business holds multiple international regulatory clearances, proprietary intellectual property protections, and audited financial compliance across key operating markets.

• Global consumer healthcare company focused on smoking harm reduction through patented, drug-free nicotine and tar reduction technology. • Core product is a liquid solution applied to cigarette filters that blocks up to 99% of tar and nicotine while allowing adult smokers to maintain their normal smoking ritual. • Targets adult smokers seeking harm reduction and gradual smoking cessation without prescription drugs or behavioural disruption. • Operates a scalable contract-manufacturing and distribution-led model with sales channels across OTC retail, pharmacies, government health programmes, and international distribution partnerships. • Built around proprietary technology with worldwide patents and trademarks protected until 20 years from now, creating long-term defensibility in the smoking cessation sector. • Regulatory clearances and ingredient approvals secured across major markets, including FDA-approved ingredients in the USA, NHS ethical clearance in the UK, TGA Australia, and approvals across 40+ countries. • Established international footprint with active or contracted distribution and government programmes across GCC countries, Africa, Australia, New Zealand, China, Japan, Singapore, Malaysia, Indonesia, Greece, and Cyprus. • Additional platform extensions planned for cigarette filter capsules, government smoking-reduction tenders, and solutions designed for the global hookah and shisha market. • Positioned to address the growing global smoking cessation and harm-reduction market estimated at over $25 billion, serving approximately 1.1 billion smokers worldwide. • Reports strong financial performance with EBITDA margins of approximately 40%, fully audited financial statements, and no bank borrowings. • Asset-light operating structure enables rapid scalability while maintaining strong profitability and international expansion flexibility. • Management has developed a long-term intellectual property monetisation strategy with an indicative IP valuation target of approximately $50 million in the next 6 years. • Business holds multiple international regulatory clearances, proprietary intellectual property protections, and audited financial compliance across key operating markets.

• Company engaged in manufacturing critical care and diagnostic medical devices, along with executing end-to-end turnkey healthcare infrastructure projects. • Core product portfolio includes patient monitoring systems, ECG machines, CPAP, and BiPAP devices, catering to hospitals and healthcare facilities. • Built strong execution capabilities with over a decade of industry experience, achieving 3x business growth over the last two years. • Among a limited set of players capable of delivering large-scale turnkey healthcare projects with faster turnaround compared to peers. • Current manufacturing facility has an installed capacity to produce devices worth INR 500–600 crore annually, operating at ~ 10% utilization, leaving significant headroom for scale. • Positioned to capitalize on large upcoming healthcare infrastructure demand, including medical colleges and multispecialty hospitals across the country. • In addition to permanent staff, employees are hired on a contract basis to meet project‑specific requirements and manage workload flexibility. • Promoter-driven business with deep domain expertise in both device manufacturing and project execution. • Operates a certified manufacturing setup with required medical device licenses, ISO, and BIS certifications, ensuring compliance and product reliability.

We are a startup business of an AI-powered medical platform, headquartered in Tel Aviv, Israel, focused on integrating cutting-edge technology into clinical environments. The company specializes in developing a core software–hardware product: an AI-powered workstation designed specifically to enhance medical practices. Our solution delivers an advanced all-in-one platform, combining ergonomic touchscreens with AI-driven capabilities to streamline healthcare workflows for physicians and improve patient interaction. The company has been operational for three years and is currently running pilot project, demonstrating the product in a real clinical setting. The company maintains parallel strategic tracks, continuing its research and development efforts while simultaneously engaging in marketing and business development activities in both the United States and Israel to build brand presence and awareness. We have showcased the product at multiple exhibitions in both markets, followed by meetings with paid, interested financial and medical entities. Our target customers include healthcare professionals, clinics, hospitals, and medical practices seeking an integrated, high-end technology solution to improve operational efficiency and patient care. Revenue generation strategies will evolve as the company strengthens its SaaS-AI solution and intensifies commercialisation efforts, with the objective of capturing market share in the digital health and AI healthcare technology sectors.

Located in Dubai, this ISO 9001 certified company specializes in the manufacture of 3D-printed dental zirconia blanks. - The business operates the first facility of its kind in the Middle East, making it a pioneer in the dental materials sector. - Their primary products are high-quality dental zirconia blocks/blanks, which are essential for creating durable dental restorations. - The target customers include dental laboratories and dental clinics, with a focus on both local and international markets. - The company utilizes advanced 3D printing technology to produce zirconia blanks, ensuring precision and superior quality. - With a production capacity targeted at approximately 2,500 blanks per month, they aim to meet growing demand in the dental industry. - Revenue is generated through the sale of dental zirconia products, tapping into an expanding market for dental supplies and equipment. - Business has Certificate of Registration and Commercial License.